NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




TEMPORARILY CLOSED Clinical Trials

RTOG-1216:  ORAL CAVITY, OROPHARYNX, LARYNX, or HYPOPHARYNX, Squamous Stg III-IV, M0, post-total resection; RT + concurrent Cisplatin or Docetaxel or Docetaxel & Cetuximab (IMRT credentialing is required – see protocol.)

Effective 2-22-16

 

 

NRG-GY005:  Ovarian, peritoneal, or fallopian tube, serous or endometrioid ca,recurrent platinum-resistant. Non platinum based std chemo vs Cediranib/Olaparib vs Cediranib alone vs Olaparib alone

 

Effective 6-16-17

 

ECOG-ACRIN EA6141:  Melanoma, unresectable stage III or stage IV, Nivolumab + Ipilimumab + or - Sargramostim (GM-CSF)

 

Effective 6-23-17

 

NRG CC003:  PCI w/wo hippocampal avoidance, small cell lung cancer, neurocognitive assessment (IMRT credentialing required)

Effective 10-13-17

 

SWOG S1318:  ALL, new dx, ≥ 65 years old.  Philadelphia negative:  Blinatumomab/POMP.  Philadelphia positive:  Dasatinib/Prednisone/Blinatumomab.  Cohort 2

Effective 9-28-17

 

Alliance A021501:  Head of pancreas, borderline resectable, T1-4, N0-1, Nx, M0, neo adjuvant chemo vs neo adjuvant chemo + RT.

Effective 5-9-18

 

Alliance A091401:  Stage IV or unresectable, measurable sarcoma, ≥ 1 prior systemic therapy, nivolumab vs. nivolumab + ipilimumab,

Effective 9-5-18

 

ARST1321:  Soft tissue sarcoma of extremity or trunk, newly diagnosed, neoadjuvant, chemo + RT vs RT +/- Pazopanib.

Effective 10-1-18

    

 

SWOG S1612:  Untreated AML or MDS with excess blasts,  ≥ 60 years of age, FLT3 testing, Azacitidine vs. Azacitidine + Nivolumab vs. Azacitidine + Midostaurin vs. Decitabine + Cytarabine         

Effective  10-22-18

 

Alliance A011106:  Neoadj., T2-T4 any N M0, ER+, post-menopausal; Anastrozole vs Fulvestrant vs both ---> Surgery ---> Endocrine therapy x 4.5 yrs (dependent on Modified PEPI score)

Effective 11-1-18

 

SWOG S1500:  Stage IV, type I or II papillary renal carcinoma, cabozantinib vs. crizotinib vs. savolitinib vs. sunitinib.

Effective 12-5-18

 

NSABP B-55:  High risk, TNBC, BRCA1 or BRCA2 positive mutation, Stage I-III, Olaparib vs Placebo post definitive local tx and chemo

Effective 12-3-18    Until Amendment 6 is approved by local IRB.

 

ECOG-ACRIN EA1131:  Adjuvant, stage II or III, post operative and neoadjuvant chemo, residual triple negative breast ca, platinum based chemo vs capecitabine

Effective 1-8-19

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

                         

 

 

 

                        

 

 

 

 

 

 






  © 2013-2019 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA